Brief: CSPC Pharma Says NMPA Accepts NDA For KN026 And HB1801 For Advanced Breast Cancer
18/08/2026 16:22
BRIEF-CSPC Pharma Says NMPA Accepts NDA For KN026 And HB1801 For Advanced Breast Cancer Aug 18 (Reuters) - CSPC PHARMACEUTICAL GROUP LIMITED 1093.HK:
NMPA ACCEPTS NEW DRUG APPLICATION FOR KN026 AND HB1801 FOR ADVANCED BREAST CANCER
Further company coverage: 1093.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines